p-AKT Expression on Clinical Outcomes in Malignant Lymphoma

Samsung Medical Center

Status: Completed

Conditions: Malignant Lymphoma; P13K-AKT Pathway Deregulation

Treatments: Other: p-AKT immunohistochemical staining

Study type: Observational

Funder types: Other

Identifiers

NCT01789060

2013-01-047

Details and patient eligibility

About

PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.

Full description

Recently, among diverse oncogenic signaling pathways, a number of studies have focused on the significance of oncogenic PI3K/AKT (phophatidylinositol 3-kinase/serine-threonine kinase, also known as protein kinase B [PKB]) pathway. PI3K(phosphatidylinositol 3-kinase)/AKT pathway phosphorylates and activates AKT as phosphorylated AKT (p-AKT) and plays a critical role promoting malignant phenotype and has prognostic significance in various solid cancers.

However, a systematic approach on the impact of p-AKT overexpression on clinical outcomes has not been performed in malignant lymphoma.

Enrollment: 262 patients

Sex: All

Ages: 17 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. the patients were pathologically confirmed of malignant lymphoma, according to the World Health Organization classification;
2. the patients had adequate paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT.

Exclusion criteria

1. Primary central nervous system lymphoma was excluded in this study

Trial design

262 participants in 1 patient group

p-AKT

Description:

p-AKT immunohistochemical staining,high p-AKT expression (upper quartile), low p-AKT expression (lower 3 quartiles)

Treatment:

Other: p-AKT immunohistochemical staining